Affinium Pharmaceuticals of Toronto has appointed new senior directors in chemistry and structural biology, and has promoted three existing senior executives: Klaus Fiebig will be the company’s new senior director of structural biology, leading its efforts in X-ray crystallography and NMR. Fiebig comes to Affinium from MRPharm of Frankfurt, Germany, where he was CEO and a co-founder. He holds a PhD in pharmaceutical chemistry from the University of California, San Francisco. Henry Pauls is the company’s new senior director of medicinal chemistry.